Paclitaxel plus ifosfamide in advanced ovarian cancer

Oncology (Switzerland)

Volumn 54, Issue 2, 1997, Pages 102-107

  Miglietta, L ^a   Amoroso, D ^a   Bruzzone, M ^a   Granetto, C ^a   Catsafados, E ^a   Mammoliti, S ^b   Guarneri, D ^c   Pedull�, F ^d   Foglia, G ^d   Ragni, K ^d   Martini, M C ^e   Brema, F ^e   Addamo, G ^c   Moraglio, L ^e   Pastorino, G ^e   Boccardo, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c Ospedale Civile   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e Servizio di Oncologia Medica   (Italy)

Author keywords

Advanced ovarian cancer; Ifosfamide; Paclitaxel

Indexed keywords

CIMETIDINE; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PACLITAXEL; PLATINUM COMPLEX; PREDNISONE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 0031054375     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227671     Document Type: Article

References (20)

1. Neijt JP, Ten Bokkcl Huinink WW, Van Der Burg M, Van Oosteron AT, Willemsc PHB, Heintz APM, et al: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma, J Clin Oncol 1987,5:1157-1168.
2. Ozols RF, Young RC: Ovarian canccr, Curr Prob Cancer 1987;11:59-122.
3. Markman M, Hakes T, Reichman B, Lewis JR, Rubin S, Jones K, et al: Ifosfamidc and mcsna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease, J Clin Oncol 1992;10:243-248.
4. Sorensen P, Pfeiffer P, Bertelsen K: A phase II trial of ifosfamide and mesna as salvage therapy in patients with ovarian canccr refractory to or relapsing after prior platinum-containing chemotherapy, Gynecol Oncol 1995;56:75-78.
5. McGuirc KP: Taxol: A new drug with significant activity as salvage therapy in advanced epithelial ovarian carcinoma, Gynecol Oncol 1993;51:78-85.
6. Thigpen JT, Blessing JA, Ball H, Hummel JJ, Barret R: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group Study, J Clin Oncol 1994; 12: 1748-1753.
7. Rose W: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies, Presented at the Second National Cancer Institute Workshop on Taxol and Taxus, 1992, Alexandria.
8. Citardi MJ, Rowinsky EK, Schaefer KL, Done-hawcr RC: Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine, Proc Am Assoc Cancer Res 1990;31:2431.
9. Klaasen U, Harstrick A, van Hoefer N, Schlcnchcr N, Stabl M, Seeber S: Activity and schedule dependent interactions of taxol, ifosfamide and etoposide in cisplatin sensitive and refractory human ovarian carcinoma cell lines as a basis for second line protocols (abstract), Ann Oncol 1994;5:98.
10. Miller AB, Hoogstraten B, Staquct M, Winkler A: Reporting results of cancer treatment, Cancer 1981;47:207-214.
11. Markman M, Hoskins W: Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population, J Clin Oncol 1992; 10:513-514.
12. McGuire WP, Hoskins W, Brady M, Kuccra PR, Look KY, Partridge EE, et al.: A phase III trial comparing cisplatin/cytoxan and cispla-tin/taxol in advanced ovarian cancer (abstract), Proc Am SocClin Oncol 1993; 12:255.
13. Lipton RB, Apfel SC, Dutchen JP, Rosemberg R, Kaplan J, Berger A, et al: Taxol produces a predominantly sensory' neuropathy, Neurology 1989;39:368-373.
14. Brade WP, Hcrdrich K, Varini M: Ifosfamide-pharmacology, safety and therapeutic potential, Cancer Treat Rev 1985;12:1-47.
15. Markman M, Rothmaan R, Hakes T, Reichman B, Hoskins W, Rubin S, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, J Clin Oncol 1991;9:389-393.
16. Blackledge G, Lawton F, Redman C, Kelly K: Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patients treatment and the design of phase II trials, BrJ Cancer 1989;59:650-653.
17. McGuire WP, Rowinsky EK, Roscnshcin NB, Grumbine FC, Ettingcr DS, Armstrong DK, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann Intern Med 1989; 111:273-279.
18. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, et al: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Treatment Referral Center 9103, J Clin Oncol 1993;11:2405-2410.
19. Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg S, et al: Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer, J Natl Canccr Inst 1994;86:18-24.
20. Eisenhauer EA, Ten Bokkel Huinink WW, Swcnerton KD, Gianni L, Myles J, Van der Burg ME, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose vs low dose and long vs short infusion, J Clin Oncol 1994;12:2654-2666.